Taiwan Liposome Company, Ltd.
DelistedCIK 1722890fmd_0HJJE0YE0X0YWQ4NKZ76R4NAA1Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Dec 31, 2020, 5 periods
Latest annual · FY2020
Millions- Total revenues
- 102
- Operating income
- (983)
- Net income
- (982)
- Free cash flow
- (908)
Bulls and bears
Loading
News summary
An AI model writes the summary on request, from this company's recent filings only, and cites each filing it uses.
AI-written
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2017 to FY2020
- +27.1%
Taiwan Liposome Company, Ltd. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2020 | FY2019 | Change | Source |
|---|---|---|---|---|
| Revenue | NT$101.9 million | NT$209.1 million | -51.3% | 20-F 2021-03-30 · proof |
| Operating income | -NT$983.1 million | -NT$801.6 million | 20-F 2021-03-30 · proof | |
| Net income | -NT$981.5 million | -NT$807.5 million | 20-F 2021-03-30 · proof | |
| Cash from operating activities | -NT$875.2 million | -NT$777.6 million | 20-F 2021-03-30 · proof | |
| Free cash flow | -NT$907.7 million | -NT$833.2 million | 20-F 2021-03-30 · proof | |
| Total assets | NT$1.7 billion | NT$1.4 billion | +26.2% | 20-F 2021-03-30 · proof |
| Total liabilities | NT$886.1 million | NT$664.1 million | +33.4% | 20-F 2021-03-30 · proof |
| Cash and cash equivalents | NT$1.3 billion | NT$1 billion | +31.1% | 20-F 2021-03-30 · proof |
| Total debt | NT$600.3 million | NT$416.7 million | +44.1% | 20-F 2021-03-30 · proof |
- What was Taiwan Liposome Company, Ltd.'s revenue in fiscal 2020?
- Taiwan Liposome Company, Ltd. reported revenue of NT$101.9 million for fiscal 2020 (the year ended Dec 31, 2020), against NT$209.1 million the year before (-51.3%). Source: the 20-F filed with the SEC on Mar 30, 2021. SEC
- What was Taiwan Liposome Company, Ltd.'s operating income in fiscal 2020?
- Taiwan Liposome Company, Ltd. reported operating income of -NT$983.1 million for fiscal 2020 (the year ended Dec 31, 2020), against -NT$801.6 million the year before. Source: the 20-F filed with the SEC on Mar 30, 2021. SEC
- What was Taiwan Liposome Company, Ltd.'s net income in fiscal 2020?
- Taiwan Liposome Company, Ltd. reported net income of -NT$981.5 million for fiscal 2020 (the year ended Dec 31, 2020), against -NT$807.5 million the year before. Source: the 20-F filed with the SEC on Mar 30, 2021. SEC
- What was Taiwan Liposome Company, Ltd.'s cash from operating activities in fiscal 2020?
- Taiwan Liposome Company, Ltd. reported cash from operating activities of -NT$875.2 million for fiscal 2020 (the year ended Dec 31, 2020), against -NT$777.6 million the year before. Source: the 20-F filed with the SEC on Mar 30, 2021. SEC
- What was Taiwan Liposome Company, Ltd.'s free cash flow in fiscal 2020?
- Taiwan Liposome Company, Ltd. reported free cash flow of -NT$907.7 million for fiscal 2020 (the year ended Dec 31, 2020), against -NT$833.2 million the year before. Source: the 20-F filed with the SEC on Mar 30, 2021. SEC
- What are Taiwan Liposome Company, Ltd.'s total assets?
- As of Dec 31, 2020, Taiwan Liposome Company, Ltd. reported total assets of NT$1.7 billion, against NT$1.4 billion a year earlier (+26.2%). Source: the 20-F filed with the SEC on Mar 30, 2021. SEC
- What are Taiwan Liposome Company, Ltd.'s total liabilities?
- As of Dec 31, 2020, Taiwan Liposome Company, Ltd. reported total liabilities of NT$886.1 million, against NT$664.1 million a year earlier (+33.4%). Source: the 20-F filed with the SEC on Mar 30, 2021. SEC
- What are Taiwan Liposome Company, Ltd.'s cash and cash equivalents?
- As of Dec 31, 2020, Taiwan Liposome Company, Ltd. reported cash and cash equivalents of NT$1.3 billion, against NT$1 billion a year earlier (+31.1%). Source: the 20-F filed with the SEC on Mar 30, 2021. SEC
- What is Taiwan Liposome Company, Ltd.'s total debt?
- As of Dec 31, 2020, Taiwan Liposome Company, Ltd. reported total debt of NT$600.3 million, against NT$416.7 million a year earlier (+44.1%). Source: the 20-F filed with the SEC on Mar 30, 2021. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1722890&period_type=annual&limit=5"Information only, not investment advice.